Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Heterozygous Familial Hypercholesterolemia
Clinical Trial
NCT03038022Last updated: 12/4/2025
MDGL
Madrigal Pharmaceuticals, Inc.
